RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+43%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$926M
AUM Growth
+$926M
(+30%)
Cap. Flow
-$7.41M
Cap. Flow
% of AUM
-0.8%
Top 10 Holdings %
Top 10 Hldgs %
29.66%
Holding
99
New
14
Increased
25
Reduced
45
Closed
5
Top Buys
| 1 |
Gilead Sciences
GILD
|
$17.7M |
| 2 |
LVGO
Livongo Health, Inc. Common Stock
LVGO
|
$9.4M |
| 3 |
Baxter International
BAX
|
$8.18M |
| 4 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$8.1M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$7.8M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$13.9M |
| 2 |
MacroGenics
MGNX
|
$9.07M |
| 3 |
Esperion Therapeutics
ESPR
|
$8.61M |
| 4 |
Neurocrine Biosciences
NBIX
|
$6.71M |
| 5 |
Nektar Therapeutics
NKTR
|
$6.6M |
Sector Composition
| 1 | Healthcare | 94.86% |
| 2 | Communication Services | 1.03% |
| 3 | Energy | 0.07% |
| 4 | Technology | 0.06% |
| 5 | Financials | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $41.7M | 4.5% | 750,000 -250,000 | -25% | -$13.9M |
|
2
Vertex Pharmaceuticals
VRTX
$100B
| $39.9M | 4.31% | 137,500 +22,500 | +20% | +$6.53M |
|
3
UnitedHealth
UNH
$281B
| $31M | 3.35% | 105,000 +25,000 | +31% | +$7.37M |
|
4
AbbVie
ABBV
$372B
| $29.5M | 3.18% | 300,000 -30,000 | -9% | -$2.95M |
|
5
BioMarin Pharmaceuticals
BMRN
$11.2B
| $23.4M | 2.53% | 190,000 +5,155 | +3% | +$636K |
|
6
Bristol-Myers Squibb
BMY
$96B
| $22.3M | 2.41% | 380,000 +30,000 | +9% | +$1.76M |
|
7
NovoCure
NVCR
$1.38B
| $22.2M | 2.4% | 375,000 +15,000 | +4% | +$890K |
|
|
8
Esperion Therapeutics
ESPR
$448M
| $21.8M | 2.36% | 425,000 -167,798 | -28% | -$8.61M |
|
9
Humana
HUM
$36.5B
| $21.3M | 2.3% | 55,000 +10,000 | +22% | +$3.88M |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $21.3M | 2.3% | 190,000 +30,000 | +19% | +$3.37M |
|
11
Cigna
CI
$80.3B
| $20.6M | 2.23% | 110,000 +5,000 | +5% | +$938K |
|
|
12
MacroGenics
MGNX
$112M
| $18.8M | 2.04% | 675,000 -325,000 | -33% | -$9.07M |
|
|
13
Nektar Therapeutics
NKTR
$568M
| $18.3M | 1.98% | 790,000 -285,000 | -27% | -$6.6M |
|
|
14
Gilead Sciences
GILD
$140B
| $17.7M | 1.91% | +230,000 | New | +$17.7M |
|
15
Eli Lilly
LLY
$657B
| $17.2M | 1.86% | 105,000 +5,000 | +5% | +$821K |
|
16
Elevance Health
ELV
$71.8B
| $17.1M | 1.85% | 65,000 | – | – |
|
17
Abbott
ABT
$231B
| $16.9M | 1.83% | 185,000 +15,000 | +9% | +$1.37M |
|
|
AXNX
18
DELISTED
Axonics, Inc. Common Stock
AXNX
| $16.5M | 1.78% | 470,000 +5,000 | +1% | +$176K |
|
|
ABMD
19
DELISTED
Abiomed Inc
ABMD
| $16.4M | 1.77% | 68,000 -20,000 | -23% | -$4.83M |
|
|
IMMU
20
DELISTED
Immunomedics Inc
IMMU
| $16.3M | 1.76% | 460,000 -130,000 | -22% | -$4.61M |
|
|
MYOK
21
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $15.5M | 1.67% | 160,000 -20,000 | -11% | -$1.93M |
|
|
BHVN
22
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $15.4M | 1.66% | 210,000 +70,000 | +50% | +$5.12M |
|
23
Jazz Pharmaceuticals
JAZZ
$7.75B
| $15.1M | 1.63% | 137,032 +17,032 | +14% | +$1.88M |
|
24
Guardant Health
GH
$8.41B
| $15M | 1.62% | 185,000 +10,000 | +6% | +$811K |
|
25
Centene
CNC
$14.3B
| $14.9M | 1.61% | 234,378 +59,378 | +34% | +$3.77M |
|